|
RAVER2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
7.42759997951481E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
9.103500E-03 |
| Stage1-vs-Stage3 |
2.780600E-01 |
| Stage1-vs-Stage4 |
2.4384999997018E-07 |
| Stage2-vs-Stage3 |
1.661570E-03 |
| Stage2-vs-Stage4 |
2.90140000025474E-07 |
| Stage3-vs-Stage4 |
2.796100E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.05899963745537E-10 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
9.540000E-01 |
| Caucasian-vs-Asian |
6.896400E-01 |
| AfricanAmerican-vs-Asian |
8.793800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.776000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62592161956354E-12 |
| Normal-vs-Age(81-100Yrs) |
7.42919999963121E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.706600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.779400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.952800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.949370E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.990800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.077200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.541030E-03 |
| Classical-VS-Follicular |
4.25239954360279E-10 |
| Classical-VS-Other |
8.333000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
6.51467768619796E-12 |
| Tall-VS-Other |
2.006000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.155800E-02 |
| Follicular-VS-Normal |
9.52620005101323E-09 |
| Other-VS-Normal |
1.82683999999655E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
2.24770000001318E-06 |
|
|
